Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations

Medicine, Pathology, Gastroenterology +16

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

Journal of Hepatology · 2016 · 4.8K citations

Medicine, Internal Medicine, Hepatology +9

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Paul Angulo, David E. Kleiner, Sanne Dam‐Larsen et al. · Gastroenterology · 2015 · 3K citations · Full text

Medicine, Internal Medicine, Pathology +12

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Mattias Ekstedt, Hannes Hagström, Patrik Nasr et al. · Hepatology · 2014 · 2.3K citations · Full text

Medicine, Internal Medicine, Pathology +17

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui et al. · Hepatology · 2023 · 2.3K citations · Full text

Medicine, Pediatrics, Hepatology +13